Clinical trial

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT02412371

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Paclitaxel Normalized identity: paclitaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo for Veliparib Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatinView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Veliparib Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention Radiotherapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2015-04-30

PhasePHASE1 / PHASE2

Conditions

Non-small Cell Lung Cancer Stage IIIunresolved

Interventions

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Placebo for VeliparibDRUG

CarboplatinDRUG · verified · RxNorm: carboplatin

VeliparibDRUG

RadiotherapyRADIATION

Sponsors & collaborators

AbbVielead sponsor

Mapped research locations

ProvidenceRhode Island, United States2 BostonMassachusetts, United States1 ChicagoIllinois, United States1 BaltimoreMaryland, United States1 DurhamNorth Carolina, United States1 Chapel HillNorth Carolina, United States1 Winston-SalemNorth Carolina, United States1 La JollaCalifornia, United States1 CharlottesvilleVirginia, United States1 SyracuseNew York, United States1 NewarkDelaware, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02412371 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.